Cargando…

Competing risk analysis of cardiovascular death in patients with primary gallbladder cancer

BACKGROUND: Developments in medical technology are resulting in continuous decreases in the cancer mortality rate of patients with gallbladder cancer, while non‐cancer deaths in cancer patients are becoming more common. The main cause of this is cardiovascular mortality (CVM). The purpose of this st...

Descripción completa

Detalles Bibliográficos
Autores principales: Chen, Chong, Xu, Fengshuo, Yuan, Shiqi, Zhao, Xuenuo, Qiao, Mengmeng, Han, Didi, Lyu, Jun
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9939154/
https://www.ncbi.nlm.nih.gov/pubmed/35920057
http://dx.doi.org/10.1002/cam4.5104
_version_ 1784890784405782528
author Chen, Chong
Xu, Fengshuo
Yuan, Shiqi
Zhao, Xuenuo
Qiao, Mengmeng
Han, Didi
Lyu, Jun
author_facet Chen, Chong
Xu, Fengshuo
Yuan, Shiqi
Zhao, Xuenuo
Qiao, Mengmeng
Han, Didi
Lyu, Jun
author_sort Chen, Chong
collection PubMed
description BACKGROUND: Developments in medical technology are resulting in continuous decreases in the cancer mortality rate of patients with gallbladder cancer, while non‐cancer deaths in cancer patients are becoming more common. The main cause of this is cardiovascular mortality (CVM). The purpose of this study was to determine the CVM risk in patients with primary gallbladder cancer (PGC). METHODS: We extracted information on patients in the SEER database who were diagnosed with PGC from 2004 to 2015, compared CVM in patients with PGC with the general United States population, and calculated standardized mortality rates (SMRs) and the absolute excess risk. A competing risks model was used to identify and analyze the independent risk factors for cardiovascular death in patients with PGC. RESULTS: This study included 5925 patients, 247 of whom died from cardiovascular disease. The SMR of cardiovascular death in patients with PGC was 15.84 (95% confidence interval: 15.83–15.85), and the SMR was slightly lower in male than female patients. The competing risks analysis indicated that age, marital status, cancer cell differentiation, chemotherapy status, and year of diagnosis were risk factors for cardiovascular death in patients with PGC. CONCLUSIONS: The CVM risk is considerably higher in patients with PGC than in the general population. It is therefore very necessary to apply cardioprotective interventions to patients with PGC.
format Online
Article
Text
id pubmed-9939154
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher John Wiley and Sons Inc.
record_format MEDLINE/PubMed
spelling pubmed-99391542023-02-20 Competing risk analysis of cardiovascular death in patients with primary gallbladder cancer Chen, Chong Xu, Fengshuo Yuan, Shiqi Zhao, Xuenuo Qiao, Mengmeng Han, Didi Lyu, Jun Cancer Med REVIEWS BACKGROUND: Developments in medical technology are resulting in continuous decreases in the cancer mortality rate of patients with gallbladder cancer, while non‐cancer deaths in cancer patients are becoming more common. The main cause of this is cardiovascular mortality (CVM). The purpose of this study was to determine the CVM risk in patients with primary gallbladder cancer (PGC). METHODS: We extracted information on patients in the SEER database who were diagnosed with PGC from 2004 to 2015, compared CVM in patients with PGC with the general United States population, and calculated standardized mortality rates (SMRs) and the absolute excess risk. A competing risks model was used to identify and analyze the independent risk factors for cardiovascular death in patients with PGC. RESULTS: This study included 5925 patients, 247 of whom died from cardiovascular disease. The SMR of cardiovascular death in patients with PGC was 15.84 (95% confidence interval: 15.83–15.85), and the SMR was slightly lower in male than female patients. The competing risks analysis indicated that age, marital status, cancer cell differentiation, chemotherapy status, and year of diagnosis were risk factors for cardiovascular death in patients with PGC. CONCLUSIONS: The CVM risk is considerably higher in patients with PGC than in the general population. It is therefore very necessary to apply cardioprotective interventions to patients with PGC. John Wiley and Sons Inc. 2022-08-03 /pmc/articles/PMC9939154/ /pubmed/35920057 http://dx.doi.org/10.1002/cam4.5104 Text en © 2022 The Authors. Cancer Medicine published by John Wiley & Sons Ltd. https://creativecommons.org/licenses/by/4.0/This is an open access article under the terms of the http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited.
spellingShingle REVIEWS
Chen, Chong
Xu, Fengshuo
Yuan, Shiqi
Zhao, Xuenuo
Qiao, Mengmeng
Han, Didi
Lyu, Jun
Competing risk analysis of cardiovascular death in patients with primary gallbladder cancer
title Competing risk analysis of cardiovascular death in patients with primary gallbladder cancer
title_full Competing risk analysis of cardiovascular death in patients with primary gallbladder cancer
title_fullStr Competing risk analysis of cardiovascular death in patients with primary gallbladder cancer
title_full_unstemmed Competing risk analysis of cardiovascular death in patients with primary gallbladder cancer
title_short Competing risk analysis of cardiovascular death in patients with primary gallbladder cancer
title_sort competing risk analysis of cardiovascular death in patients with primary gallbladder cancer
topic REVIEWS
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9939154/
https://www.ncbi.nlm.nih.gov/pubmed/35920057
http://dx.doi.org/10.1002/cam4.5104
work_keys_str_mv AT chenchong competingriskanalysisofcardiovasculardeathinpatientswithprimarygallbladdercancer
AT xufengshuo competingriskanalysisofcardiovasculardeathinpatientswithprimarygallbladdercancer
AT yuanshiqi competingriskanalysisofcardiovasculardeathinpatientswithprimarygallbladdercancer
AT zhaoxuenuo competingriskanalysisofcardiovasculardeathinpatientswithprimarygallbladdercancer
AT qiaomengmeng competingriskanalysisofcardiovasculardeathinpatientswithprimarygallbladdercancer
AT handidi competingriskanalysisofcardiovasculardeathinpatientswithprimarygallbladdercancer
AT lyujun competingriskanalysisofcardiovasculardeathinpatientswithprimarygallbladdercancer